Diffusion Pharmaceuticals Inc. (DFFN) |
| 4.4 0.41 (10.28%) 08-16 16:00 |
| Open: | 4.23 |
| High: | 5.19 |
| Low: | 4.165 |
| Volume: | 349,445 |
| Market Cap: | 9(M) |
| PE Ratio: | -0.62 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 5.19 |
| Resistance 1: | 4.80 |
| Pivot price: | 0.00 |
| Support 1: | 4.16 |
| Support 2: | 3.47 |
| 52w High: | 14.37 |
| 52w Low: | 4.139999 |
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 15 Aug 2023
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma - GlobeNewswire
Thu, 30 Mar 2023
Diffusion to merge with EIP Pharma in all-stock deal - Seeking Alpha
Thu, 30 Mar 2023
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company ... - Yahoo Finance
Thu, 17 Nov 2022
LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion Pharmaceuticals - GlobeNewswire
Tue, 25 Oct 2022
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including ... - GlobeNewswire
Mon, 18 Apr 2022
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
